Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway

Figure 5 Changes of phosphorylated-inhibitor of nuclear factor-κB and p65 expression before and after treatment with Iguratimod. A: Western blot analysis of the effect of Iguratimod on expression of phosphorylated inhibitor of nuclear factor-κB and p65; B: Ratio of phosphorylated inhibitor of nuclear factor-κB (p-IκB) and p65 to the gray value of the internal reference glyceraldehyde-3-phosphate dehydrogenase (GAPDH) before and after treatment, ^aP < 0.05.